Qiagen N.V. Common Shares (QGEN)

FairStock Score: 60/100 — STEADY

Key Financials

Strengths

• Generates $257 million in annual free cash flow (3.3% yield on market cap)
• Solid return on equity of 11.6% above cost of capital
• Conservative balance sheet with debt-to-equity of just 0.49, providing financial flexibility

AI Analysis

Qiagen N.V. Common Shares is a small-cap healthcare company valued at $7.8 billion. The business generates $2.1 billion in annual revenue with a 5.2% net margin and $257 million in free cash flow. From a quality standpoint, Qiagen shows solid Piotroski F-Score of 6/9 and Altman Z-Score of 2.9 in the grey zone. On valuation, the stock is reasonably priced at 18.6x earnings, with trades above its Graham Number with a negative 30% margin. Growth dynamics show revenue growing at 3.7% and profit growth of 22.1%. Our composite FairStock Score of 60/100 reflects above-average fundamentals overall. Investors should weigh the business quality against the current price and their own margin of safety requirements.

Bull Case

Improving fundamentals and sector tailwinds could drive meaningful earnings growth, compressing the effective multiple for patient investors. With $257 million in annual free cash flow (3.3% yield), management has ample capital for buybacks, dividends, or accretive acquisitions.

Bear Case

Macro headwinds or sector-specific disruption could pressure margins, particularly if competitive intensity increases in the healthcare space. Regulatory changes, input cost inflation, or demand normalization represent underappreciated risks that could materially impact forward estimates.

Data from SEC filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer